CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 05 2020
19 05 2020
Historique:
received:
30
07
2019
accepted:
24
04
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
7
1
2021
Statut:
epublish
Résumé
Many Alzheimer's disease (AD) genes including Apolipoprotein E (APOE) are found to be expressed in blood-derived macrophages and thus may alter blood protein levels. We measured 91 neuro-proteins in plasma from 316 participants of the Rotterdam Study (incident AD = 161) using Proximity Extension Ligation assay. We studied the association of plasma proteins with AD in the overall sample and stratified by APOE. Findings from the Rotterdam study were replicated in 186 AD patients of the BioFINDER study. We further evaluated the correlation of these protein biomarkers with total tau (t-tau), phosphorylated tau (p-tau) and amyloid-beta (Aβ) 42 levels in cerebrospinal fluid (CSF) in the Amsterdam Dementia Cohort (N = 441). Finally, we conducted a genome-wide association study (GWAS) to identify the genetic variants determining the blood levels of AD-associated proteins. Plasma levels of the proteins, CDH6 (β = 0.638, P = 3.33 × 10
Identifiants
pubmed: 32427856
doi: 10.1038/s41598-020-65038-5
pii: 10.1038/s41598-020-65038-5
pmc: PMC7237496
doi:
Substances chimiques
Apolipoprotein E4
0
Biomarkers
0
Cadherins
0
Thiolester Hydrolases
EC 3.1.2.-
hydroxyacylglutathione hydrolase
EC 3.1.2.6
K cadherin
U9G6UFV40X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8233Références
Au, R., Piers, R. J. & Lancashire, L. Back to the future: Alzheimer’s disease heterogeneity revisited. Alzheimers Dement (Amst) 1, 368–370 (2015).
Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–3 (1993).
pubmed: 8346443
doi: 10.1126/science.8346443
Corder, E. H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7, 180–4 (1994).
pubmed: 7920638
doi: 10.1038/ng0694-180
Seshadri, S., Drachman, D. A. & Lippa, C. F. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer’s disease. What physicians know, and what they should know. Arch Neurol 52, 1074–9 (1995).
pubmed: 7487559
doi: 10.1001/archneur.1995.00540350068018
van der Lee, S. J. et al. The effect of APOE and other common genetic variants on the onset of Alzheimer’s disease and dementia: a community-based cohort study. Lancet Neurol 17, 434–444 (2018).
pubmed: 29555425
doi: 10.1016/S1474-4422(18)30053-X
Fernandez, C. G., Hamby, M. E., McReynolds, M. L. & Ray, W. J. The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer’s Disease. Frontiers in aging neuroscience 11, 14 (2019).
pubmed: 30804776
pmcid: 6378415
doi: 10.3389/fnagi.2019.00014
Sunderland, T. et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56, 670–6 (2004).
pubmed: 15522251
doi: 10.1016/j.biopsych.2004.07.021
de la Torre, J. C. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3, 184–90 (2004).
pubmed: 14980533
doi: 10.1016/S1474-4422(04)00683-0
Larsson, S. C. et al. Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis. BMJ 359, j5375 (2017).
pubmed: 29212772
pmcid: 5717765
doi: 10.1136/bmj.j5375
Henstridge, C.M., Hyman, B.T. & Spires-Jones, T.L. Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis. Nature Reviews Neuroscience 1 (2019).
Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51, 414–430 (2019).
pubmed: 30820047
pmcid: 6463297
doi: 10.1038/s41588-019-0358-2
Colonna, M. TREMs in the immune system and beyond. Nat Rev Immunol 3, 445–53 (2003).
pubmed: 12776204
doi: 10.1038/nri1106
Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience 12, 723 (2011).
pubmed: 22048062
pmcid: 4036520
doi: 10.1038/nrn3114
Katusic, Z. S. & Austin, S. A. Endothelial nitric oxide: protector of a healthy mind. European heart journal 35, 888–894 (2013).
pubmed: 24357508
pmcid: 3977136
doi: 10.1093/eurheartj/eht544
Koizumi, K., Wang, G. & Park, L. Endothelial dysfunction and amyloid-β-induced neurovascular alterations. Cellular and molecular neurobiology 36, 155–165 (2016).
pubmed: 26328781
doi: 10.1007/s10571-015-0256-9
Han, B. H. et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-β peptide, partial restoration via γ-secretase inhibition. Journal of Neuroscience 28, 13542–13550 (2008).
pubmed: 19074028
doi: 10.1523/JNEUROSCI.4686-08.2008
Tong, X.-K., Lecrux, C. & Hamel, E. Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits. Journal of neuroscience 32, 4705–4715 (2012).
pubmed: 22492027
doi: 10.1523/JNEUROSCI.0169-12.2012
Park, L. et al. Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Abeta Peptides. Circ Res 121, 258–269 (2017).
pubmed: 28515043
pmcid: 5522360
doi: 10.1161/CIRCRESAHA.117.311054
Hye, A. et al. Proteome-based plasma biomarkers for Alzheimer’s disease. Brain 129, 3042–50 (2006).
pubmed: 17071923
doi: 10.1093/brain/awl279
Ray, S. et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nature medicine 13, 1359 (2007).
pubmed: 17934472
doi: 10.1038/nm1653
Soares, H. D. et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Archives of neurology 69, 1310–1317 (2012).
pubmed: 22801723
pmcid: 3683865
doi: 10.1001/archneurol.2012.1070
Ringman, J. M. et al. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Archives of neurology 69, 757–764 (2012).
pubmed: 22689192
pmcid: 3668092
Hu, W. T. et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897–905 (2012).
pubmed: 22855860
pmcid: 3425844
doi: 10.1212/WNL.0b013e318266fa70
Llano, D. A., Devanarayan, V. & Simon, A. J., Alzheimer’s Disease Neuroimaging, I. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Disease & Associated Disorders 27, 233–243 (2013).
doi: 10.1097/WAD.0b013e31826d597a
Whelan, C. D. et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. Acta neuropathologica communications 7, 1–14 (2019).
doi: 10.1186/s40478-019-0795-2
Blankenburg, M., Haberland, L., Elvers, H. D., Tannert, C. & Jandrig, B. High-Throughput Omics Technologies: Potential Tools for the Investigation of Influences of EMF on Biological Systems. Curr Genomics 10, 86–92 (2009).
pubmed: 19794880
pmcid: 2699823
doi: 10.2174/138920209787847050
Bell, R. D. et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512–6 (2012).
pubmed: 22622580
pmcid: 22622580
doi: 10.1038/nature11087
Phizicky, E., Bastiaens, P. I., Zhu, H., Snyder, M. & Fields, S. Protein analysis on a proteomic scale. Nature 422, 208–15 (2003).
pubmed: 12634794
doi: 10.1038/nature01512
Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769–773 (2018).
pubmed: 30072576
pmcid: 6190714
doi: 10.1126/science.aaq1327
Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 (2018).
pubmed: 29875488
pmcid: 6697541
doi: 10.1038/s41586-018-0175-2
Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. Nature Precedings, 1-1 (2010).
Zhao, B. et al. Genome-wide association analysis of 19,629 individuals identifies variants influencing regional brain volumes and refines their genetic co-architecture with cognitive and mental health traits. Nature genetics 51, 1637–1644 (2019).
pubmed: 31676860
pmcid: 6858580
doi: 10.1038/s41588-019-0516-6
Harper, L. et al. Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. Journal of Neurology, Neurosurgery & Psychiatry 88, 908–916 (2017).
doi: 10.1136/jnnp-2016-314978
Sutphen, C. L. et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease. Alzheimers Dement 14, 869–879 (2018).
pubmed: 29580670
pmcid: 6110083
doi: 10.1016/j.jalz.2018.01.012
Hesse, C. et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neuroscience letters 297, 187–190 (2001).
pubmed: 11137759
doi: 10.1016/S0304-3940(00)01697-9
Lv, J. et al. Quantitative proteomics reveals that PEA15 regulates astroglial Abeta phagocytosis in an Alzheimer’s disease mouse model. J Proteomics 110, 45–58 (2014).
pubmed: 25108202
doi: 10.1016/j.jprot.2014.07.028
Ye, L. et al. Abeta seeding potency peaks in the early stages of cerebral beta-amyloidosis. EMBO Rep 18, 1536–1544 (2017).
pubmed: 28701326
pmcid: 5579388
doi: 10.15252/embr.201744067
Asada‐Utsugi, M. et al. N‐cadherin enhances APP dimerization at the extracellular domain and modulates Aβ production. Journal of neurochemistry 119, 354–363 (2011).
pubmed: 21699541
pmcid: 3395082
doi: 10.1111/j.1471-4159.2011.07364.x
Henriques, A. G. et al. Altered protein phosphorylation as a resource for potential AD biomarkers. Sci Rep 6, 30319 (2016).
pubmed: 27466139
pmcid: 4964585
doi: 10.1038/srep30319
Gul, I. S., Hulpiau, P., Saeys, Y. & van Roy, F. Evolution and diversity of cadherins and catenins. Exp Cell Res 358, 3–9 (2017).
pubmed: 28268172
doi: 10.1016/j.yexcr.2017.03.001
Fannon, A. M. & Colman, D. R. A model for central synaptic junctional complex formation based on the differential adhesive specificities of the cadherins. Neuron 17, 423–34 (1996).
pubmed: 8816706
doi: 10.1016/S0896-6273(00)80175-0
Obst-Pernberg, K. & Redies, C. Cadherins and synaptic specificity. J Neurosci Res 58, 130–8 (1999).
pubmed: 10491578
doi: 10.1002/(SICI)1097-4547(19991001)58:1<130::AID-JNR13>3.0.CO;2-8
Yamagata, M., Duan, X. & Sanes, J. R. Cadherins Interact With Synaptic Organizers to Promote Synaptic Differentiation. Front Mol Neurosci 11, 142 (2018).
pubmed: 29760652
pmcid: 5936767
doi: 10.3389/fnmol.2018.00142
Arikkath, J. & Reichardt, L. F. Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity. Trends Neurosci 31, 487–94 (2008).
pubmed: 18684518
pmcid: 2623250
doi: 10.1016/j.tins.2008.07.001
Sancisi, V. et al. Cadherin 6 is a new RUNX2 target in TGF-beta signalling pathway. PLoS One 8, e75489 (2013).
pubmed: 24069422
pmcid: 3772092
doi: 10.1371/journal.pone.0075489
Clay, M. R. & Halloran, M. C. Cadherin 6 promotes neural crest cell detachment via F-actin regulation and influences active Rho distribution during epithelial-to-mesenchymal transition. Development 141, 2506–15 (2014).
pubmed: 24917505
pmcid: 4050695
doi: 10.1242/dev.105551
Montagne, A. et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302 (2015).
pubmed: 25611508
pmcid: 4350773
doi: 10.1016/j.neuron.2014.12.032
Inoue, T., Tanaka, T., Suzuki, S. C. & Takeichi, M. Cadherin-6 in the developing mouse brain: expression along restricted connection systems and synaptic localization suggest a potential role in neuronal circuitry. Dev Dyn 211, 338–51 (1998).
pubmed: 9566953
doi: 10.1002/(SICI)1097-0177(199804)211:4<338::AID-AJA5>3.0.CO;2-I
Kuhn, P.H. et al. Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function. Elife 5 (2016).
Malinverno, M. et al. Synaptic localization and activity of ADAM10 regulate excitatory synapses through N-cadherin cleavage. Journal of Neuroscience 30, 16343–16355 (2010).
pubmed: 21123580
doi: 10.1523/JNEUROSCI.1984-10.2010
Marambaud, P. et al. A CBP binding transcriptional repressor produced by the PS1/ϵ-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114, 635–645 (2003).
pubmed: 13678586
doi: 10.1016/j.cell.2003.08.008
Andreyeva, A. et al. C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-beta. Brain 135, 2140–54 (2012).
pubmed: 22637581
doi: 10.1093/brain/aws120
Hu, N. W. et al. Extracellular Forms of Abeta and Tau from iPSC Models of Alzheimer’s Disease Disrupt Synaptic Plasticity. Cell Rep 23, 1932–1938 (2018).
pubmed: 29768194
pmcid: 5972225
doi: 10.1016/j.celrep.2018.04.040
Togashi, H. et al. Cadherin regulates dendritic spine morphogenesis. Neuron 35, 77–89 (2002).
pubmed: 12123610
doi: 10.1016/S0896-6273(02)00748-1
Chen, F. et al. Role for glyoxalase I in Alzheimer’s disease. Proc Natl Acad Sci USA 101, 7687–92 (2004).
pubmed: 15128939
doi: 10.1073/pnas.0402338101
Thornalley, P. J. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269, 1–11 (1990).
pubmed: 2198020
pmcid: 1131522
doi: 10.1042/bj2690001
Xu, Y. & Chen, X. Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family. J Biol Chem 281, 26702–13 (2006).
pubmed: 16831876
doi: 10.1074/jbc.M604758200
Desai, K. M. et al. Oxidative stress and aging: is methylglyoxal the hidden enemy? Can J Physiol Pharmacol 88, 273–84 (2010).
pubmed: 20393592
doi: 10.1139/Y10-001
Takeuchi, M. et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease. Curr Alzheimer Res 1, 39–46 (2004).
pubmed: 15975084
doi: 10.2174/1567205043480582
Ko, S. Y., Lin, Y. P., Lin, Y. S. & Chang, S. S. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 49, 474–80 (2010).
pubmed: 20471471
doi: 10.1016/j.freeradbiomed.2010.05.005
Wang, J. Z., Wang, Z. H. & Tian, Q. Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer’s disease. Neurosci Bull 30, 359–66 (2014).
pubmed: 24627329
pmcid: 5562660
doi: 10.1007/s12264-013-1415-y
More, S. S., Vartak, A. P. & Vince, R. Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer’s disease. ACS Chem Neurosci 4, 330–8 (2013).
pubmed: 23421684
doi: 10.1021/cn3001679
Kuhla, B. et al. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer’s disease brains. Neurobiol Aging 28, 29–41 (2007).
pubmed: 16427160
doi: 10.1016/j.neurobiolaging.2005.11.007
Shea, T. B., Rogers, E., Ashline, D., Ortiz, D. & Sheu, M. S. Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radic Biol Med 33, 1115–20 (2002).
pubmed: 12374623
doi: 10.1016/S0891-5849(02)01001-8
Baldeiras, I. et al. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer’s disease. J Alzheimers Dis 15, 117–28 (2008).
pubmed: 18780972
doi: 10.3233/JAD-2008-15110
Guidi, I. et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 27, 262–9 (2006).
pubmed: 16399211
doi: 10.1016/j.neurobiolaging.2005.01.001
Hofman, A. et al. The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol 30, 661–708 (2015).
pubmed: 26386597
pmcid: 4579264
doi: 10.1007/s10654-015-0082-x
Folstein, M. F., Folstein, S. E. & McHugh, P. R. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189–98 (1975).
pubmed: 1202204
doi: 10.1016/0022-3956(75)90026-6
Copeland, J. R. et al. A semi-structured clinical interview for the assessment of diagnosis and mental state in the elderly: the Geriatric Mental State Schedule. I. Development and reliability. Psychol Med 6, 439–49 (1976).
pubmed: 996204
doi: 10.1017/S0033291700015889
Roth, M. et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149, 698–709 (1986).
pubmed: 3790869
doi: 10.1192/bjp.149.6.698
McKhann, G. et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–44 (1984).
pubmed: 6610841
doi: 10.1212/WNL.34.7.939
Ott, A., Breteler, M. M., van Harskamp, F., Stijnen, T. & Hofman, A. Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 147, 574–80 (1998).
pubmed: 9521184
doi: 10.1093/oxfordjournals.aje.a009489
Brann, E. et al. Inflammatory markers in late pregnancy in association with postpartum depression-A nested case-control study. Psychoneuroendocrinology 79, 146–159 (2017).
pubmed: 28285186
doi: 10.1016/j.psyneuen.2017.02.029
Slooter, A. J. et al. Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study. J Neurol 246, 304–8 (1999).
pubmed: 10367700
doi: 10.1007/s004150050351
Slooter, A. J. et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 55, 964–8 (1998).
pubmed: 9678314
doi: 10.1001/archneur.55.7.964
Roshchupkin, G. V. et al. Fine-mapping the effects of Alzheimer’s disease risk loci on brain morphology. Neurobiol Aging 48, 204–211 (2016).
pubmed: 27718423
doi: 10.1016/j.neurobiolaging.2016.08.024
McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 48, 1279–83 (2016).
pubmed: 27548312
pmcid: 5388176
doi: 10.1038/ng.3643
Das, S. et al. Next-generation genotype imputation service and methods. Nat Genet 48, 1284–7 (2016).
pubmed: 27571263
pmcid: 5157836
doi: 10.1038/ng.3656
Delaneau, O. & Marchini, J. Genomes Project, C. & Genomes Project, C. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. Nat Commun 5, 3934 (2014).
pubmed: 25653097
pmcid: 4338501
doi: 10.1038/ncomms4934
Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 44, 955–9 (2012).
pubmed: 22820512
pmcid: 3696580
doi: 10.1038/ng.2354
Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282–9 (2014).
pubmed: 25155658
doi: 10.1001/jamaneurol.2014.1358
van der Flier, W. M. & Scheltens, P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimers Dis 62, 1091–1111 (2018).
pubmed: 29562540
pmcid: 5870023
doi: 10.3233/JAD-170850
van der Flier, W. M. et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer’s disease 41, 313–327 (2014).
pubmed: 24614907
doi: 10.3233/JAD-132306
Reijs, B. L. R. et al. The Central Biobank and Virtual Biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases. Frontiers in neurology 6, 216 (2015).
pubmed: 26528237
pmcid: 4606063
doi: 10.3389/fneur.2015.00216
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the royal statistical society. Series B (Methodological), 289–300 (1995).
Zhan, X., Hu, Y., Li, B., Abecasis, G. R. & Liu, D. J. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. Bioinformatics 32, 1423–6 (2016).
pubmed: 27153000
pmcid: 4848408
doi: 10.1093/bioinformatics/btw079
Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun 8, 1826 (2017).
pubmed: 5705698
pmcid: 5705698
doi: 10.1038/s41467-017-01261-5
Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 580–5 (2013).
doi: 10.1038/ng.2653